The performance of the integrated VS pipeline on the FDA-approved antiangiogenic agents.
| Drugbank ID | Drug name | Structure | Company | LibDock Score | Bayesian model (NB-c) | |
|---|---|---|---|---|---|---|
| EstPGood | Prediction | |||||
| DB00398 | Sorafenib |
|
Bayer | 148.031 | 1 | True |
| DB01268 | Sunitinib |
|
Pfizer | 125.116 | 0.978 | True |
| DB06589 | Pazopanib |
|
GSK | 136.442 | 0.986 | True |
| DB05294 | Vandetanib |
|
AstraZeneca | 126.119 | 0.997 | True |
| DB06626 | Axitinib |
|
Pfizer | 144.994 | 0.953 | True |
| DB08896 | Regorafenib |
|
Bayer | 139.278 | 1 | True |
| DB08875 | Cabozantinib |
|
Exelixis | 127.297 | 1 | True |
| DB09078 | Lenvatinib |
|
Eisai | 140.146 | 0.979 | True |